北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 血液科  > 期刊论文
学科主题: 临床医学
题名:
Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase
作者: Jiang, Qian; Xu, Lan-Ping; Liu, Dai-Hong; Liu, Kai-Yan; Chen, Shan-Shan; Jiang, Bin; Jiang, Hao; Chen, Huan; Chen, Yu-Hong; Han, Wei; Zhang, Xiao-Hui; Wang, Yu; Qin, Ya-Zhen; Liu, Yan-Rong; Lai, Yue-Yun; Huang, Xiao-Jun
刊名: BLOOD
发表日期: 2011-03-17
DOI: 10.1182/blood-2010-09-308510
卷: 117, 期:11, 页:3032-3040
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Hematology
研究领域[WOS]: Hematology
关键词[WOS]: CHRONIC MYELOID-LEUKEMIA ; ABL TYROSINE KINASE ; HLA-MISMATCHED/HAPLOIDENTICAL BLOOD ; WORLD-HEALTH-ORGANIZATION ; MARROW-TRANSPLANTATION ; CYTOGENETIC RESPONSES ; BLAST CRISIS ; FOLLOW-UP ; PHILADELPHIA-CHROMOSOME ; WORKING PARTY
英文摘要:

The relative merits of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and imatinib for chronic myelogenous leukemia in the accelerated phase (AP-CML) have not previously been evaluated. This cohort study was designed to compare the outcomes of imatinib (n = 87) versus allo-HSCT (n = 45) for AP-CML. A multivariate analysis of the total population revealed that a CML duration > 12 months, hemoglobin < 100 g/L, and peripheral blood blasts > 5% were independent adverse prognostic factors for both overall survival (OS) and progression-free survival (PFS). Both treatments resulted in similar survival in low-risk (no factor) patients, with 6-year event-free survival (EFS), OS, and PFS rates of more than 80.0%. Intermediate-risk (any factor) patients showed no difference in EFS and OS, but 6-year PFS rates were 55.7% versus 92.9% (P = .047) with imatinib versus allo-HSCT, respectively. Among high-risk (at least 2 factors) patients, imatinib was by far inferior to allo-HSCT, with 5-year EFS, OS, and PFS rates of 9.3% versus 66.7% (P = .034), 17.7% versus 100% (P = .008), and 18.8% versus 100% (P = .006), respectively. We conclude that allo-HSCT confers significant survival advantages for high-and intermediate-risk patients with AP-CML compared with imatinib treatment; however, the outcomes of the 2 therapies are equally good in low-risk patients. All trials were registered with the Chinese Clinical Trial Registry (www.chictr.org) as CHiCTR-TNC-10000955. (Blood. 2011; 117(11): 3032-3040)

语种: 英语
所属项目编号: 30725038 ; IRT0702
项目资助者: National Outstanding Young Scientists&prime ; Foundation of China ; University of China
WOS记录号: WOS:000288496300012
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/53542
Appears in Collections:北京大学第二临床医学院_血液科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: Peking Univ, Inst Hematol, Peoples Hosp, Beijing 100044, Peoples R China

Recommended Citation:
Jiang, Qian,Xu, Lan-Ping,Liu, Dai-Hong,et al. Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase[J]. BLOOD,2011,117(11):3032-3040.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Jiang, Qian]'s Articles
[Xu, Lan-Ping]'s Articles
[Liu, Dai-Hong]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Jiang, Qian]‘s Articles
[Xu, Lan-Ping]‘s Articles
[Liu, Dai-Hong]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace